Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Syntara Limited ( (AU:SNT) ) has provided an update.
Syntara Limited announced the presentation of preclinical findings and clinical data from its Phase 2a trial of amsulostat at the American Society of Hematology Annual Meeting. The company is advancing its development of amsulostat, which has shown promise in treating myelofibrosis, and is exploring further clinical and commercial pathways with potential collaborators. This development could enhance Syntara’s positioning in the hematological malignancies market and provide new opportunities for stakeholders.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited is a clinical-stage drug development company specializing in targeting extracellular matrix dysfunction. It utilizes expertise in amine oxidase chemistry to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company is listed on the Australian Securities Exchange and is based in Sydney, Australia.
Average Trading Volume: 2,438,015
Technical Sentiment Signal: Sell
Current Market Cap: A$50.6M
Learn more about SNT stock on TipRanks’ Stock Analysis page.